BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31759358)

  • 21. Overexpression of CCDC69 activates p14
    Cui L; Zhou F; Chen C; Wang CC
    J Ovarian Res; 2019 Jan; 12(1):4. PubMed ID: 30651135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Shin D; Kim EH; Lee J; Roh JL
    Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
    Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
    Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 as a target for ellagic acid‑mediated suppression of prostate cancer cells in vitro.
    Mohammed Saleem YI; Selim MI
    Oncol Rep; 2020 Sep; 44(3):1255-1265. PubMed ID: 32705219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
    Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
    Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Golgi-SNARE GS28 potentiates cisplatin-induced apoptosis by forming GS28-MDM2-p53 complexes and by preventing the ubiquitination and degradation of p53.
    Sun NK; Huang SL; Chien KY; Chao CC
    Biochem J; 2012 Jun; 444(2):303-14. PubMed ID: 22397410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxico-pharmacological evaluations of the small-molecule LQFM166: Inducer of apoptosis and MDM2 antagonist.
    Dos Santos TRM; Garcia da Silva AC; de Carvalho FS; Sanz G; Vaz BG; Lião LM; Menegatti R; Valadares MC
    Chem Biol Interact; 2018 Sep; 293():20-27. PubMed ID: 30057354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
    Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
    Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53.
    Yip HT; Chopra R; Chakrabarti R; Veena MS; Ramamurthy B; Srivatsan ES; Wang MB
    Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):317-26. PubMed ID: 16549753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
    Rew Y; Sun D; Yan X; Beck HP; Canon J; Chen A; Duquette J; Eksterowicz J; Fox BM; Fu J; Gonzalez AZ; Houze J; Huang X; Jiang M; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Saiki AY; Shaffer P; Wang YC; Wortman S; Yakowec P; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
    J Med Chem; 2014 Dec; 57(24):10499-511. PubMed ID: 25384157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
    Mu Z; Hachem P; Agrawal S; Pollack A
    Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA.
    Jiang T; Zhou C; Gu J; Liu Y; Zhao L; Li W; Wang G; Li Y; Cai L
    Cancer Lett; 2013 Aug; 337(1):133-42. PubMed ID: 23726840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.
    Weilbacher A; Gutekunst M; Oren M; Aulitzky WE; van der Kuip H
    Cell Death Dis; 2014 Jul; 5(7):e1318. PubMed ID: 25010984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms of synergistic induction of apoptosis by the combination therapy with hyperthermia and cisplatin in prostate cancer cells.
    Zhang JF; Yan XM; Lan B; Lei YR; Li XH; Gao S; Guo YF; Guo F
    Biochem Biophys Res Commun; 2016 Oct; 479(2):159-165. PubMed ID: 27524236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.